Therapeutic Asset Ratings
414 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Bdc-3042
Colorectal Cancer
Bolt Biotherapeutics, Inc.
P1
C
(36)
bi 765063
Colorectal Cancer
Boehringer Ingelheim
P1
C
(36)
Bl-M17D1
Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
Bpi-442096
Colorectal Cancer
Betta Pharmaceuticals Co., Ltd.
P1
C
(36)
Budigalimab
Colorectal Cancer
AbbVie
P1
C
(36)
Cadvec
Colorectal Cancer
Baylor College of Medicine
P1
C
(36)
Cbi-1214
Colorectal Cancer
Cartography Biosciences
P1
C
(36)
Cea-Targeted Car-T
Colorectal Cancer
Weijia Fang, MD
P1
C
(36)
Certepetide
Colorectal Cancer
University of California, San Diego
P1
C
(36)
Chimeric Antigen Receptor Modified T Cells Infusion
Colorectal Cancer
Shanghai Cell Therapy Group Co.,Ltd
P1
C
(36)
Clsp-5282
Colorectal Cancer
Clasp Therapeutics, Inc.
P1
C
(36)
coq10
Colorectal Cancer
toqa saad mohammed mohammed
P1
C
(36)
CRX100
Colorectal Cancer
BioEclipse Therapeutics
P1
C
(36)
ct-202
Colorectal Cancer
Context Therapeutics Inc.
P1
C
(36)
ct-95
Colorectal Cancer
Context Therapeutics Inc.
P1
C
(36)
Dat-2645
Colorectal Cancer
Danatlas Pharmaceuticals Co., Ltd
P1
C
(36)
Disp-10
Colorectal Cancer
Dispatch Biotherapeutics
P1
C
(36)
dk210
Colorectal Cancer
DEKA Biosciences
P1
C
(36)
Dp Cd8 Til
Colorectal Cancer
AgonOx, Inc.
P1
C
(36)
Drug: Ibi3028
Colorectal Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
P1
C
(36)
Elvn-002
Colorectal Cancer
Enliven Therapeutics
P1
C
(36)
ft536
Colorectal Cancer
Fate Therapeutics
P1
C
(36)
ft836
Colorectal Cancer
Fate Therapeutics
P1
C
(36)
[Ga-68]-PNT6555
Colorectal Cancer
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
C
(36)
gh21
Colorectal Cancer
Suzhou Genhouse Bio Co., Ltd.
P1
C
(36)
Showing 276 to 300 of 414 assets
Previous
Page 12 of 17
Next